Natera, Inc. (NTRA)
After hours:
| Previous close | 95.55 |
| Open | 108.00 |
| Bid | 105.02 x 100 |
| Ask | 105.31 x 400 |
| Day's range | 101.02 - 108.32 |
| 52-week range | 36.90 - 108.32 |
| Volume | |
| Avg. volume | 1,408,854 |
| Market cap | 12.871B |
| Beta (5Y monthly) | 1.38 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Natera Reports First Quarter 2024 Financial Results
AUSTIN, Texas, May 09, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2024.
- Business Wire
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
AUSTIN, Texas, May 03, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to detect recurrence early in patients with early-stage breast cancer. The full study can be found here.
- Business Wire
Natera to Report its First Quarter 2024 Results on May 9
AUSTIN, Texas, May 01, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2024, after the market close on May 9, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
